# EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

> **NCT03638167** · PHASE1 · COMPLETED · sponsor: **Seattle Children's Hospital** · enrollment: 11 (actual)

## Conditions studied

- Central Nervous System Tumor, Pediatric
- Glioma
- Ependymoma
- Medulloblastoma
- Germ Cell Tumor
- Atypical Teratoid/Rhabdoid Tumor
- Primitive Neuroectodermal Tumor
- Choroid Plexus Carcinoma
- Pineoblastoma

## Interventions

- **BIOLOGICAL:** EGFR806-specific chimeric antigen receptor (CAR) T cell

## Key facts

- **NCT ID:** NCT03638167
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2023-12-22
- **Final completion:** 2023-12-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03638167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03638167, "EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03638167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*